ES2194198T3 - Criba de agentes para el tratamiento de la enfermedad de alzheimer. - Google Patents

Criba de agentes para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
ES2194198T3
ES2194198T3 ES97923188T ES97923188T ES2194198T3 ES 2194198 T3 ES2194198 T3 ES 2194198T3 ES 97923188 T ES97923188 T ES 97923188T ES 97923188 T ES97923188 T ES 97923188T ES 2194198 T3 ES2194198 T3 ES 2194198T3
Authority
ES
Spain
Prior art keywords
agent
alzheimer
disease
filaments
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97923188T
Other languages
English (en)
Inventor
Michel Goedert
Ross Jakes
Maria Grazia Spillantini
Masato Hasegawa
Michael John Smith
Richard Anthony Crowther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2194198T3 publication Critical patent/ES2194198T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

UN PROCEDIMIENTO PARA CLASIFICAR UN AGENTE PARA SU POSIBLE USO EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER COMPRENDE HACER REACCIONAR, EN PRESENCIA DEL AGENTE, LA PROTEINA TAU CON UN CARBOHIDRATO SULFATADO ADECUADO, EN CONDICIONES APROPIADAS PARA FORMAR FILAMENTOS, Y CONTROLAR LA PRESENCIA DE FILAMENTOS. LA PROTEINA TAU Y EL CARBOHIDRATO SULFATADO, POR EJEMPLO, UN GLUCOSAMINOGLUCANO SULFATADO, REACCIONARAN EN CONDICIONES APROPIADAS FORMANDO FILAMENTOS, BIEN SEA FILAMENTOS HELICOIDALES EN PARES O FILAMENTOS RECTOS. SI LA FORMACION DE FILAMENTOS QUEDA AFECTADA CUANDO LA REACCION SE REALIZA EN PRESENCIA DE UN AGENTE QUE SE DESEA CLASIFICAR, ESTO SE DEBE POSIBLEMENTE A UN EFECTO DE INTERFERENCIA, INHIBICION O BLOQUEO DEL AGENTE. UN AGENTE QUE INHIBA EL CONJUNTO DE PHF IN VITRO PODRIA TENER TAMBIEN UN EFECTO INHIBIDOR IN VIVO Y, EN CONSECUENCIA, POSEER UN VALOR TERAPEUTICO EN POTENCIA PARA RETRASAR LOS EFECTOS DEMENCIALES DE LA ENFERMEDAD DE ALZHEIMER. LA INVENCION PUEDE PROPORCIONAR ASI UNMETODO DE CLASIFICACION QUE IDENTIFIQUE AGENTES QUE MEREZCAN UNA INVESTIGACION PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER.
ES97923188T 1996-05-23 1997-05-20 Criba de agentes para el tratamiento de la enfermedad de alzheimer. Expired - Lifetime ES2194198T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9610829.5A GB9610829D0 (en) 1996-05-23 1996-05-23 Screening of agents for treatment of azlheimers disease

Publications (1)

Publication Number Publication Date
ES2194198T3 true ES2194198T3 (es) 2003-11-16

Family

ID=10794213

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97923188T Expired - Lifetime ES2194198T3 (es) 1996-05-23 1997-05-20 Criba de agentes para el tratamiento de la enfermedad de alzheimer.

Country Status (10)

Country Link
US (1) US6245575B1 (es)
EP (1) EP0901633B1 (es)
JP (1) JP2001503509A (es)
AT (1) ATE235058T1 (es)
DE (1) DE69719978T2 (es)
DK (1) DK0901633T3 (es)
ES (1) ES2194198T3 (es)
GB (1) GB9610829D0 (es)
PT (1) PT901633E (es)
WO (1) WO1997044669A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5757598A (en) * 1996-12-13 1998-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease
JP4469281B2 (ja) 2002-11-01 2010-05-26 プロテオテック・インコーポレーテッド 硫酸化グリコサミノグリカンによる、アルツハイマー病アミロイド斑形成の迅速な誘導
FR2888937B1 (fr) * 2005-07-21 2012-10-26 Biomerieux Sa Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
KR101095630B1 (ko) * 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제
JP2013032295A (ja) * 2009-12-04 2013-02-14 Kaneka Corp タウ蛋白の吸着材および吸着除去システム
JP2020515846A (ja) * 2017-03-28 2020-05-28 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． タウタンパク質凝集を調節する化合物の検出のための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5705401A (en) 1991-11-12 1998-01-06 The University Of Melbourne Method of assaying for alzheimer's disease
EP0911390B1 (en) * 1991-12-06 2009-08-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis

Also Published As

Publication number Publication date
EP0901633A1 (en) 1999-03-17
WO1997044669A1 (en) 1997-11-27
PT901633E (pt) 2003-07-31
EP0901633B1 (en) 2003-03-19
DE69719978T2 (de) 2003-12-18
DK0901633T3 (da) 2003-06-16
ATE235058T1 (de) 2003-04-15
GB9610829D0 (en) 1996-07-31
US6245575B1 (en) 2001-06-12
JP2001503509A (ja) 2001-03-13
DE69719978D1 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
EE200100645A (et) Amüloidogeense haiguse preventsioon ja ravi
BR9909382A (pt) Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
TW264480B (es)
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
EA200200111A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
DE69526120D1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
ATE325343T1 (de) Diagnose und behandlung von arthritischen erkrankungen
NO962130L (no) Synergistisk behandling av Parkinsons sykdom
RU93004982A (ru) Способ лечения эндотоксинового шока с применением антиадгезивных антител
ES2194198T3 (es) Criba de agentes para el tratamiento de la enfermedad de alzheimer.
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69013871D1 (de) 4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
EP1039931A4 (en) MULTIVALENT RECOMBINANT ANTIBODIES FOR THE TREATMENT OF HUMAN RHINOVIRUS (HRV) INFECTIONS
NO984651D0 (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
NO20012849D0 (no) Ny terapeutisk anvendelse for hepariner med lav molekylvekt
NO961496L (no) Behandling av allergiske sykdommer med terfenadinkarboksylat
FR2786099B1 (fr) Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline
WO1998022495A3 (en) De-analoques and derivatives of bradykinin 1-5 fragment(bk1-5) and their retropeptides having antikinin activity and uses thereof